PDCD1 and urothelial carcinoma: Immune checkpoint inhibitors (ICIs), particularly programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies, have transformed the treatment of advanced urothelial carcinoma (8–10).